Acquisition Announced
Ipsen acquisition of Kartos Therapeutics
US$450m consideration
Announced 29 Jun 2026
Advisers
Ipsen
Acquirer
- Legal adviser
- Orrick

Team: Tony Chan, Ramy Shweiky, Esther Kang, Mary Ann Gallucci, Charlie Kauffman, Jason D. Flaherty, Karen Cannon, Eric Wall, David Sharrow, Esteban De La Torre, Georgia Ravitz, Craig Falls, Danielle Mangogna, Jeanine P. McGuinness, Shruthi Maganti, Christina Bouchot, Shannon Yavorsky, Shari Esfahani, Carly Owens, Peter Graham, Nicole Walsh, Robin Freedman
- Target
- Kartos Therapeutics
- Acquirer
- Ipsen
- Target based in
- United States
- Buyer based in
- France
- Sector
- Biotech
- Tags
- Biotech, Oncology
In the league tables
Similar deals
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
Sources
- 29 Jun 2026 Orrick Advises Ipsen on Acquisition of Kartos Therapeutics for up to $1.75 Billion orrick.com
- 29 Jun 2026 Press release (GlobeNewswire), Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline globenewswire.com
